ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,827.04
0.00%
US Tech 100
20,098.80
-0.93%
Dow Jones
41,938.45
0.00%
Brent Oil
79.795
-1.02%
Bitcoin
90,738.06
-3.98%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. USOTC

  6. Hemostemix Inc (PK) (HMTXF) Quote

Hemostemix Inc (PK)

Hemostemix Inc (PK) (HMTXF)

USOTC
0.167
0.00
(0.00%)
Closed January 13 4:00PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
0.167
Bid
0.0903
Ask
0.1798
Volume
-
0.00 Day's Range 0.00
0.024 52 Week Range 0.1719
Market Cap
23.654M
Previous Close
0.167
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
16,865
Shares Outstanding
141,641,969
Dividend Yield
-
PE Ratio
-13.56
Earnings Per Share (EPS)
-0.02
Revenue
200k
Net Profit
-2.5M

About Hemostemix Inc (PK)

Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has 87 patents on the derivation of angiogenic cell precursors (ACP-01), neuronal cell precursors (NCP-01) and cardiomyocyte cell precursors (CCP-01) fro... Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has 87 patents on the derivation of angiogenic cell precursors (ACP-01), neuronal cell precursors (NCP-01) and cardiomyocyte cell precursors (CCP-01) from a synergetic cell population that is sourced from the patient's blood. The Company is selling exempt compassionate treatments to individuals afflicted with critical limb ischemia, for example, and conducting clinical trials to commercialize its lead product, ACP-01, for the treatment of critical limb ischemia and peripheral arterial disease, and heart disease (ischemic cardiomyopathy, dilated cardiomyopathy). Show more

Sector
Pharmaceutical Preparations
Industry
Blank Checks
Website
www.hemostemix.com
Headquarters
Calgary, Alberta, Can
Founded
2014
Hemostemix Inc (PK) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker HMTXF. The last closing price for Hemostemix (PK) was $0.17. Over the last year, Hemostemix (PK) shares have traded in a share price range of $ 0.024 to $ 0.1719.

Hemostemix (PK) currently has 141,641,969 shares outstanding. The market capitalization of Hemostemix (PK) is $23.65 million. Hemostemix (PK) has a price to earnings ratio (PE ratio) of -13.56.

Ask ADVFN Intelligence (AI)

HMTXF Latest News

More News

Financing & Partnership News Send Shares of this Stem-Cell Therapy Company on a Tear

While most stock indices are in the red today, shares of this pioneering stem cell firm are soaring following this morning's news of an LOI. In a press release this morning, Hemostemix Inc To read...

June 03 2024
AllPennyStocks.com

HEMOSTEMIX ANNOUNCES CLOSING OF UNIT PRIVATE PLACEMENT

  HEMOSTEMIX ANNOUNCES CLOSING OF UNIT PRIVATE PLACEMENT     May 10, 2021, Calgary, Alberta -- InvestorsHub NewsWire -- Hemostemix Inc...

May 11 2021
InvestorsHub NewsWire

Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up & HMTXF Up-list

 Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up & HMTXF Up-list  Calgary, Alberta, April 23, 2021-- InvestorsHub NewsWire -- Hemostemix Inc. ("Hemostemix" or the...

April 26 2021
InvestorsHub NewsWire

Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates

  Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and  Litigation Updates   Calgary, Alberta, April 12, 2021-- InvestorsHub NewHemostemix Inc...

April 12 2021
InvestorsHub NewsWire

Hemostemix Announces it is Trading on the Frankfurt Stock Exchange and it has Retained HE Capital Markets Ltd.

Hemostemix Annonces it is Trading on the Frankfurt Stock Exchange and it has Retained HE Capital Markets LTD.   Calgary, Alberta, April 8, 2021 -- InvestorsHub NewsWire...

April 09 2021
InvestorsHub NewsWire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.099145.5882352940.0680.17190.068590450.15186859CS
40.1172235.3413654620.04980.17190.04641289710.1311043CS
120.089114.1025641030.0780.17190.0323168650.10417007CS
260.1385485.9649122810.02850.17190.024247940.06443454CS
520.1076181.1447811450.05940.17190.024189340.05988362CS
1560.0482540.63157894740.118750.32790.024214650.13593632CS
2600.16213308.163265310.00490.43720.0049344040.08284891CS

HMTXF - Frequently Asked Questions (FAQ)

What is the current Hemostemix (PK) share price?
The current share price of Hemostemix (PK) is $ 0.167
How many Hemostemix (PK) shares are in issue?
Hemostemix (PK) has 141,641,969 shares in issue
What is the market cap of Hemostemix (PK)?
The market capitalisation of Hemostemix (PK) is USD 23.65M
What is the 1 year trading range for Hemostemix (PK) share price?
Hemostemix (PK) has traded in the range of $ 0.024 to $ 0.1719 during the past year
What is the PE ratio of Hemostemix (PK)?
The price to earnings ratio of Hemostemix (PK) is -13.56
What is the cash to sales ratio of Hemostemix (PK)?
The cash to sales ratio of Hemostemix (PK) is 171.43
What is the reporting currency for Hemostemix (PK)?
Hemostemix (PK) reports financial results in CAD
What is the latest annual turnover for Hemostemix (PK)?
The latest annual turnover of Hemostemix (PK) is CAD 200k
What is the latest annual profit for Hemostemix (PK)?
The latest annual profit of Hemostemix (PK) is CAD -2.5M
What is the registered address of Hemostemix (PK)?
The registered address for Hemostemix (PK) is SUITE 1150, 707-7TH AVE SW, CALGARY, CALGARY, ALBERTA, T2P 3H6
What is the Hemostemix (PK) website address?
The website address for Hemostemix (PK) is www.hemostemix.com
Which industry sector does Hemostemix (PK) operate in?
Hemostemix (PK) operates in the BLANK CHECKS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AABVFAberdeen International Inc (PK)
$ 0.0242
(0.00%)
0
AABKFAareal Bank AG (PK)
$ 0.00
(0.00%)
0
AABBAsia Broadband Inc (PK)
$ 0.03055
(0.00%)
0
AAALYAareal Bank AG (PK)
$ 34.65
(0.00%)
0
AAAIFAlternative Investment Trust (PK)
$ 0.55
(0.00%)
0
AABVFAberdeen International Inc (PK)
$ 0.0242
(0.00%)
0
AABKFAareal Bank AG (PK)
$ 0.00
(0.00%)
0
AABBAsia Broadband Inc (PK)
$ 0.03055
(0.00%)
0
AAALYAareal Bank AG (PK)
$ 34.65
(0.00%)
0
AAAIFAlternative Investment Trust (PK)
$ 0.55
(0.00%)
0
MMEXMMEX Resources Corporation (PK)
$ 0.0001
(0.00%)
5M
OGCIFOceanaGold Philippines Inc OGP (GM)
$ 0.00
(0.00%)
1.6M
BDMMFBurgundy Diamond Mines Ltd (PK)
$ 0.02
(0.00%)
800k
KPRSFKeepers Holdings Inc (PK)
$ 0.00
(0.00%)
513k
ALSTAllstar Health Brands Inc (PK)
$ 0.00045
(0.00%)
500k

HMTXF Discussion

View Posts
JamesMacho JamesMacho 1 year ago
Investors in $HEM are still waiting for any positive financial data to emerge, but so far, it's been a disappointing journey.
👍️0
tw0122 tw0122 1 year ago
Boom boom time
👍️0

Your Recent History

USOTC
HMTXF
Hemostemix (PK)
NASDAQ
FFGWX
Brandes Us Equity Fund S...
NASDAQ
CEYEX
Ci Investment Grade Bond...
AQSE
VWRL.GB
Vanguard Ftse Allworld U...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads